GBT
JAZZ icon

Grove Bank & Trust’s Jazz Pharmaceuticals JAZZ Stock Holding History

Grove Bank & Trust’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-345
Closed -$48K – 305
2015
Q4 		$48K Buy
+345
New +$47.8K 0.04% 181

Other funds holding JAZZ

PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Grove Bank & Trust's JAZZ Position: Q1 2016 in Review

Grove Bank & Trust sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2016, closing a stake of 345 shares — an estimated $48K sold.

Grove Bank & Trust first reported a position in JAZZ in Q4 2015 and held it in 1 quarter. The position peaked at $48K in Q4 2015. 339 funds tracked by Wall St. Rank hold JAZZ as of Q1 2016.

  • Grove Bank & Trust reported no remaining Jazz Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Grove Bank & Trust sold 345 Jazz Pharmaceuticals shares in Q1 2016, an estimated $48K.
  • Grove Bank & Trust first reported a position in Jazz Pharmaceuticals in Q4 2015 and held it in 1 quarter.
  • Grove Bank & Trust's Jazz Pharmaceuticals position peaked at $48K in Q4 2015.
  • 339 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2016.

Based on Grove Bank & Trust's 13F filing for Q1 2016, filed 11 May 2016.